[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5927 Introduced in House (IH)]

<DOC>






115th CONGRESS
  2d Session
                                H. R. 5927

   To amend the Public Health Service Act to expand, intensify, and 
coordinate research and other activities of the National Institutes of 
Health with respect to prenatal opioid exposure and neonatal abstinence 
                               syndrome.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              May 23, 2018

  Mr. Soto (for himself and Mr. Fitzpatrick) introduced the following 
    bill; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
   To amend the Public Health Service Act to expand, intensify, and 
coordinate research and other activities of the National Institutes of 
Health with respect to prenatal opioid exposure and neonatal abstinence 
                               syndrome.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Neonatal Abstinence Syndrome Best 
Practice Act''.

SEC. 2. RESEARCH ON PRENATAL OPIOID EXPOSURE AND NEONATAL ABSTINENCE 
              SYNDROME.

    Part B of title IV of the Public Health Service Act is amended by 
inserting after section 409J (42 U.S.C. 284q) the following new 
section:

``SEC. 409K. PRENATAL OPIOID EXPOSURE AND NEONATAL ABSTINENCE SYNDROME.

    ``(a) Research.--The Director of NIH shall expand, intensify, and 
coordinate research and other activities of the National Institutes of 
Health with respect to the prevention, identification, and treatment of 
prenatal opioid exposure and neonatal abstinence syndrome. Such 
research and activities shall include the evaluation of treatment 
options, including with respect to--
            ``(1) the impact on short-term and long-term clinical 
        outcomes and costs of pharmacological and non-pharmacological 
        treatment options for infants with opioid withdrawal syndrome; 
        and
            ``(2) innovative care models to transition mothers and 
        babies affected by such exposure and syndrome out of the 
        hospital through outpatient follow-up programs and other 
        interdisciplinary post-discharge programs.
    ``(b) Best Practices.--Based on the research and activities 
conducted pursuant to subsection (a), the Director of NIH shall--
            ``(1) establish, and update as necessary, best practices 
        for screening and treating pregnant women for opioid use 
        disorder and for screening for neonatal abstinence syndrome and 
        opioid withdrawal syndrome among infants exposed to opioids 
        during pregnancy; and
            ``(2) disseminate such best practices to interested 
        stakeholders.''.
                                 <all>